Zealand Pharma A/S announced changes to its Executive Management. Following the resignation of Britt Meelby Jensen on 26 November 2018, the Board of Directors has decided that Britt will be released from her duties as President and CEO as of 28 February 2019. Adam Steensberg, MD, Executive Vice President and Chief Medical and Development Officer is appointed interim CEO as of 1 March 2019, while also maintaining his current responsibilities.

After nine years of dedicated service, Mats Blom, Chief Financial Officer, will leave Zealand end March 2019.